Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 168303, 6 pages
Research Article

Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry

1Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine, 315 East Broadway, Room 311, Louisville, KY 40292, USA
2Norton Radiology, Norton Hospital, 301 South Floyd Street, Louisville, Ky 40202, USA
3Baptist Health, Little Rock, AR 23011, USA

Received 28 September 2011; Revised 28 November 2011; Accepted 1 December 2011

Academic Editor: Dirk Arnold

Copyright © 2012 Raffi Kotoyan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. There has been limited reporting on the use of hepatic-directed therapy in liver dominant hepatic metastases arising from pancreatic cancer. Methods. An IRB-approved prospective multi-institutional treatment registry of 885 patients undergoing 1458 treatments for primary or secondary cancers in the liver was evaluated from January 2007 to January 2011. Results. Ten patients underwent a total of 17 treatment sessions with drug-eluting beads (DEBs). Six patients received concurrent chemotherapy while undergoing DEB with no severe adverse events. After a median followup of 16 months, the 6- and 12-month response rates were 80% and 75%, respectively, with a median overall survival of 9.3 months. Conclusion. Hepatic arterial therapy with DEB can be safely and effectively used in selected patients with liver predominant metastatic disease from pancreatic cancer. This therapy should be considered in combination with systemic chemotherapy as a possible second therapy given the limited response rates of second-line chemotherapy.